Literature DB >> 10553697

The future of the quinolones.

V T Andriole1.   

Abstract

This review emphasises the advances in the development of newer quinolones: their broader antimicrobial activity particularly their increased activity against Pneumococcus and anaerobes; their longer half-life and tissue penetration including activity in cerebrospinal fluid; and their excellent efficacy in respiratory, intra-abdominal, pelvic, and skin and soft tissue infections. Also, considerable progress has been made in our understanding of the development of bacterial resistance to the newer quinolones. Additional advances in quinolone development are likely to provide better compounds for clinical use.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10553697     DOI： 10.2165/00003495-199958002-00001

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  41 in total

1.  In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.

Authors:  E J Giamarellos-Bourboulis; H Sambatakou; P Grecka; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

2.  Nalidixic acid and bacterial chromosome replication.

Authors:  G C Crumplin; J T Smith
Journal:  Nature       Date:  1976-04-15       Impact factor: 49.962

Review 3.  Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples.

Authors:  H Nikaido; D G Thanassi
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

4.  Pharmacokinetics of three newer quinolones in pregnant and lactating women.

Authors:  H Giamarellou; E Kolokythas; G Petrikkos; J Gazis; D Aravantinos; P Sfikakis
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

5.  Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes.

Authors:  K E Aldridge; D Ashcraft; K A Bowman
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance.

Authors:  Y Dong; C Xu; X Zhao; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

8.  Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa.

Authors:  A Kitamura; K Hoshino; Y Kimura; I Hayakawa; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

9.  Improved bactericidal activity of Q-35 against quinolone-resistant staphylococci.

Authors:  T Ito; M Matsumoto; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

10.  Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.

Authors:  L J Piddock; M Johnson; V Ricci; S L Hill
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191
View more
  8 in total

Review 1.  Management of children with prolonged fever of unknown origin and difficulties in the management of fever of unknown origin in children in developing countries.

Authors:  G O Akpede; G I Akenzua
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Aetiology and management of children with acute fever of unknown origin.

Authors:  G O Akpede; G I Akenzua
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 3.  Safety profile of the fluoroquinolones: focus on levofloxacin.

Authors:  Hans H Liu
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

Review 4.  Gatifloxacin: a review of its use in the management of bacterial infections.

Authors:  Caroline M Perry; Douglas Ormrod; Miriam Hurst; Susan V Onrust
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.

Authors:  S J Martin; R Jung; C G Garvin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

6.  Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.

Authors:  Roberto Leone; Mauro Venegoni; Domenico Motola; Ugo Moretti; Valentina Piazzetta; Alfredo Cocci; Domenico Resi; Federico Mozzo; Giampaolo Velo; Liliana Burzilleri; Nicola Montanaro; Anita Conforti
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

7.  Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.

Authors:  David T Chung; Cheng-Yuan Tsai; Shu-Jen Chen; Li-Wen Chang; Chi-Hsin R King; Ching-Hung Hsu; Kit-Mui Chiu; Hao-Chen Tan; Yu-Ting Chang; Ming-Chu Hsu
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

8.  Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.

Authors:  Luke Lin; Li-Wen Chang; Cheng-Yuan Tsai; Ching-Hung Hsu; David T Chung; William S Aronstein; Funmi Ajayi; Barbara Kuzmak; Robert A Lyon
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.